advanced hodgkin’s lymphoma Latest Research Papers

Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments

Annals of Hematology ◽

10.1007/s00277-020-04344-4 ◽

2020 ◽

Vol 100 (1) ◽

pp. 303-304

Author(s):

Alessia Bari ◽

◽

Raffaella Marcheselli ◽

Stefano Sacchi ◽

Alessandro Re ◽

...

Keyword(s):

Prognostic Factors ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2020.03.005 ◽

2020 ◽

Author(s):

Najmaddin Khoshnaw ◽

Ahmed K. Yassin ◽

Sana J. Dlawar ◽

Alaa F. Alwan ◽

Parween Kh. Ismael ◽

...

Keyword(s):

Bone Marrow ◽

Bone Marrow Transplantation ◽

Marrow Transplantation ◽

Hodgkin’S Lymphoma ◽

Autologous Bone Marrow Transplantation ◽

Autologous Bone Marrow ◽

Hodgkin's Lymphoma ◽

Bone Marrow Necrosis ◽

Autologous Bone ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Interim-response-adapted therapy in advanced Hodgkin's lymphoma: Current status

Indian Journal of Medical and Paediatric Oncology ◽

10.4103/ijmpo.ijmpo_276_19 ◽

2019 ◽

Vol 40 (4) ◽

pp. 566

Author(s):

Prasanth Ganesan

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Current Status ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30500-x ◽

2018 ◽

Vol 19 (10) ◽

pp. 1328-1337 ◽

Cited By ~ 18

Author(s):

Richard A Anderson ◽

Rachel Remedios ◽

Amy A Kirkwood ◽

Pip Patrick ◽

Linsey Stevens ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Ovarian Function ◽

Secondary Analysis ◽

Hodgkin's Lymphoma ◽

Phase 3 ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Brentuximab vedotin for advanced Hodgkin's lymphoma

The Lancet Oncology ◽

10.1016/s1470-2045(17)30845-8 ◽

2017 ◽

Vol 18 (12) ◽

pp. 1566-1568 ◽

Cited By ~ 2

Author(s):

Michelle A Fanale

Keyword(s):

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

First-Line Therapy for Patients with Advanced Hodgkin’s Lymphoma: Efficacy and Toxicity of Intensive ЕАСОРР-14 Program (NN Blokhin National Medical Cancer Research Center Data)

Clinical oncohematology ◽

10.21320/2500-2139-2017-10-4-443-452 ◽

2017 ◽

Vol 10 (4) ◽

pp. 443-452

Author(s):

EA Demina ◽

◽

AA Leont’eva ◽

GS Tumyan ◽

YuE Ryabukhina ◽

...

Keyword(s):

Cancer Research ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Research Center ◽

First Line ◽

National Medical ◽

First Line Therapy ◽

Line Therapy ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-017-3714-4 ◽

2017 ◽

Vol 44 (8) ◽

pp. 1254-1257 ◽

Cited By ~ 5

Author(s):

Elif Hindié ◽

Charles Mesguich ◽

Krimo Bouabdallah ◽

Noël Milpied

Keyword(s):

Fdg Pet ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

End Of Treatment ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program

Clinical oncohematology ◽

10.21320/2500-2139-2017-10-2-150-157 ◽

2017 ◽

Vol 10 (2) ◽

pp. 150-157 ◽

Cited By ~ 1

Author(s):

EA Demina ◽

◽

AA Leont’eva ◽

GS Tumyan ◽

YuE Ryabukhina ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Positron Emission ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma

The Lancet Oncology ◽

10.1016/s1470-2045(17)30085-2 ◽

2017 ◽

Vol 18 (4) ◽

pp. 416-418 ◽

Cited By ~ 3

Author(s):

Michael Crump

Keyword(s):

Fdg Pet ◽

Hodgkin’S Lymphoma ◽

Pet Scan ◽

Hodgkin's Lymphoma ◽

Fdg Pet Scan ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?

Current Treatment Options in Oncology ◽

10.1007/s11864-017-0460-6 ◽

2017 ◽

Vol 18 (3) ◽

Cited By ~ 3

Author(s):

Peter Johnson ◽

Jemma Longley

Keyword(s):

Hodgkin’S Lymphoma ◽

Standard Of Care ◽

Hodgkin's Lymphoma ◽

Advanced Hodgkin’S Lymphoma

Download Full-text

advanced hodgkin’s lymphoma
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?

Interim-response-adapted therapy in advanced Hodgkin's lymphoma: Current status

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Brentuximab vedotin for advanced Hodgkin's lymphoma

First-Line Therapy for Patients with Advanced Hodgkin’s Lymphoma: Efficacy and Toxicity of Intensive ЕАСОРР-14 Program (NN Blokhin National Medical Cancer Research Center Data)

Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained

Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program

Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?

Export Citation Format

advanced hodgkin’s lymphomaRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?

Interim-response-adapted therapy in advanced Hodgkin's lymphoma: Current status

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Brentuximab vedotin for advanced Hodgkin's lymphoma

First-Line Therapy for Patients with Advanced Hodgkin’s Lymphoma: Efficacy and Toxicity of Intensive ЕАСОРР-14 Program (NN Blokhin National Medical Cancer Research Center Data)

Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained

Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program

Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?

advanced hodgkin’s lymphoma
Recently Published Documents